Swelling characteristics and biocompatibility of ionic liquid based hydrogels for biomedical applications

PLoS One. 2020 Apr 20;15(4):e0231421. doi: 10.1371/journal.pone.0231421. eCollection 2020.

Abstract

Polymers are commonly used in medical device manufacturing, e.g. for drug delivery systems, bone substitutes and stent coatings. Especially hydrogels exhibit very promising properties in this field. Hence, the development of new hydrogel systems for customized application is of great interest, especially regarding the swelling behavior and mechanical properties as well as the biocompatibility. The aim of this work was the preparation and investigation of various polyelectrolyte and poly-ionic liquid based hydrogels accessible by radical polymerization. The obtained polymers were covalently crosslinked with N,N'-methylenebisacrylamide (MBAA) or different lengths of poly(ethyleneglycol)diacrylate (PEGDA). The effect of different crosslinker-to-monomer ratios has been examined. In addition to the compression curves and the maximum degree of swelling, the biocompatibility with L929 mouse fibroblasts of these materials was determined in direct cell seeding experiments and the outcome for the different hydrogels was compared.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrylamides / chemistry
  • Animals
  • Biocompatible Materials / chemistry*
  • Biocompatible Materials / pharmacology
  • Cell Line
  • Cell Survival / drug effects
  • Compressive Strength
  • Hydrogels / chemistry*
  • Hydrogels / pharmacology
  • Ionic Liquids / chemistry*
  • Mice
  • Polyethylene Glycols / chemistry

Substances

  • Acrylamides
  • Biocompatible Materials
  • Hydrogels
  • Ionic Liquids
  • poly(ethylene glycol)diacrylate
  • Polyethylene Glycols
  • N,N'-methylenebisacrylamide

Grants and funding

We acknowledge financial support by Deutsche Forschungsgemeinschaft and University of Rostock within the funding programme Open Access Publishing. Funding by the Federal Ministry of Education and Research within RESPONSE "Partnership for Innovation in Implant Technology" (FKZ 03ZZ0910B) is gratefully acknowledged.